The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Multiple Sclerosis, Chronic Progressive

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Multiple Sclerosis, Chronic Progressive


Psychiatry related information on Multiple Sclerosis, Chronic Progressive


High impact information on Multiple Sclerosis, Chronic Progressive


Chemical compound and disease context of Multiple Sclerosis, Chronic Progressive


Biological context of Multiple Sclerosis, Chronic Progressive


Anatomical context of Multiple Sclerosis, Chronic Progressive


Gene context of Multiple Sclerosis, Chronic Progressive


Analytical, diagnostic and therapeutic context of Multiple Sclerosis, Chronic Progressive


  1. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. Sharief, M.K., Hentges, R. N. Engl. J. Med. (1991) [Pubmed]
  2. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. Croxford, J.L., Miller, S.D. J. Clin. Invest. (2003) [Pubmed]
  3. Detailed analysis of the oligodendrocyte myelin glycoprotein gene in four patients with neurofibromatosis 1 and primary progressive multiple sclerosis. Johnson, M.R., Ferner, R.E., Bobrow, M., Hughes, R.A. J. Neurol. Neurosurg. Psychiatr. (2000) [Pubmed]
  4. Characterization of JC virus DNA amplified from urine of chronic progressive multiple sclerosis patients. Stoner, G.L., Agostini, H.T., Ryschkewitsch, C.F., Baumhefner, R.W., Tourtellotte, W.W. Mult. Scler. (1996) [Pubmed]
  5. Working memory impairment among persons with chronic progressive multiple sclerosis. Grigsby, J., Ayarbe, S.D., Kravcisin, N., Busenbark, D. J. Neurol. (1994) [Pubmed]
  6. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. Trotter, J.L., Clifford, D.B., Anderson, C.B., van der Veen, R.C., Hicks, B.C., Banks, G. N. Engl. J. Med. (1988) [Pubmed]
  7. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. Balashov, K.E., Khoury, S.J., Hafler, D.A., Weiner, H.L. J. Clin. Invest. (1995) [Pubmed]
  8. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Hartung, H.P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S.P., Krapf, H., Zwingers, T. Lancet (2002) [Pubmed]
  9. Cladribine in treatment of chronic progressive multiple sclerosis. Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R., Zyroff, J., Beutler, E. Lancet (1994) [Pubmed]
  10. Magnetic resonance in monitoring the treatment of multiple sclerosis. Miller, D.H. Ann. Neurol. (1994) [Pubmed]
  11. Biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis. Dippel, D.W., Oomes, P.G., Visser, L.H. Ann. Neurol. (1995) [Pubmed]
  12. The neuroendocrine axis in patients with multiple sclerosis. Wei, T., Lightman, S.L. Brain (1997) [Pubmed]
  13. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Carter, J.L., Hafler, D.A., Dawson, D.M., Orav, J., Weiner, H.L. Neurology (1988) [Pubmed]
  14. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Goodkin, D.E., Kinkel, R.P., Weinstock-Guttman, B., VanderBrug-Medendorp, S., Secic, M., Gogol, D., Perryman, J.E., Uccelli, M.M., Neilley, L. Neurology (1998) [Pubmed]
  15. Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. Warshawsky, I., Rudick, R.A., Staugaitis, S.M., Natowicz, M.R. Ann. Neurol. (2005) [Pubmed]
  16. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. Booth, D.R., Arthur, A.T., Teutsch, S.M., Bye, C., Rubio, J., Armati, P.J., Pollard, J.D., Heard, R.N., Stewart, G.J. J. Mol. Med. (2005) [Pubmed]
  17. Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis. McDonnell, G.V., Kirk, C.W., Middleton, D., Droogan, A.G., Hawkins, S.A., Patterson, C.C., Graham, C.A. J. Neurol. (1999) [Pubmed]
  18. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Amirzargar, A., Mytilineos, J., Yousefipour, A., Farjadian, S., Scherer, S., Opelz, G., Ghaderi, A. Eur. J. Immunogenet. (1998) [Pubmed]
  19. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Karaszewski, J.W., Reder, A.T., Anlar, B., Kim, W.C., Arnason, B.G. Ann. Neurol. (1991) [Pubmed]
  20. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Plumb, J., McQuaid, S., Mirakhur, M., Kirk, J. Brain Pathol. (2002) [Pubmed]
  21. Multiple sclerosis: remyelination in acute lesions. Raine, C.S., Wu, E. J. Neuropathol. Exp. Neurol. (1993) [Pubmed]
  22. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. Lamers, K.J., Uitdehaag, B.M., Hommes, O.R., Doesburg, W., Wevers, R.A., von Geel, W.J. J. Neurol. Neurosurg. Psychiatr. (1988) [Pubmed]
  23. Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations. Oger, J., Kastrukoff, L., O'Gorman, M., Paty, D.W. J. Neuroimmunol. (1986) [Pubmed]
  24. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Leppert, D., Ford, J., Stabler, G., Grygar, C., Lienert, C., Huber, S., Miller, K.M., Hauser, S.L., Kappos, L. Brain (1998) [Pubmed]
  25. Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. Trotter, J.L., Collins, K.G., van der Veen, R.C. J. Neuroimmunol. (1991) [Pubmed]
  26. CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. Mäurer, M., Ponath, A., Kruse, N., Rieckmann, P. J. Neuroimmunol. (2002) [Pubmed]
  27. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. Wilczak, N., Ramsaransing, G.S., Mostert, J., Chesik, D., De Keyser, J. Mult. Scler. (2005) [Pubmed]
  28. The treatment of chronic progressive multiple sclerosis with cladribine. Beutler, E., Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R., Zyroff, J. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  29. Memory disturbance in chronic progressive multiple sclerosis. Rao, S.M., Hammeke, T.A., McQuillen, M.P., Khatri, B.O., Lloyd, D. Arch. Neurol. (1984) [Pubmed]
  30. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. Inglese, M., Mancardi, G.L., Pagani, E., Rocca, M.A., Murialdo, A., Saccardi, R., Comi, G., Filippi, M. J. Neurol. Neurosurg. Psychiatr. (2004) [Pubmed]
  31. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. Hommers, O.R., Lamers, K.J., Reekers, P. J. Neurol. (1980) [Pubmed]
  32. Lymphocyte subpopulations in multiple sclerosis: spontaneous and mitogen-induced activity. Brinkman, C.J., Nillesen, W.M., Hommes, O.R. Clin. Immunol. Immunopathol. (1984) [Pubmed]
WikiGenes - Universities